Royal Bank of Canada
MPLT

Royal Bank of Canada’s MapLight Therapeutics MPLT Stock Holding History

Royal Bank of Canada’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17K Buy
+474
New +$13.6K ﹤0.01% 6427
2026
Q1 		– Sell
-582
Closed -$10K – 7944
2025
Q4 		$10K Buy
+582
New +$9.75K ﹤0.01% 6439

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Royal Bank of Canada's MPLT Position: Q2 2026 in Review

Royal Bank of Canada opened a new position in MapLight Therapeutics (MPLT) in Q2 2026: 474 shares worth $17K. The stake represents ﹤0.01% of the portfolio and ranks #6427 among its holdings. This is a return to the name: Royal Bank of Canada previously reported a position in MPLT as recently as Q4 2025.

Royal Bank of Canada first reported a position in MPLT in Q4 2025 and has held it in 2 quarters since. 100 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • Royal Bank of Canada held 474 shares of MapLight Therapeutics worth $17K as of Q2 2026.
  • MapLight Therapeutics was a new Royal Bank of Canada position in Q2 2026.
  • MapLight Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #6427 holding.
  • Royal Bank of Canada first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 100 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.